Xenikos B.V. secured €40 million in convertible debt from Veloxis Pharmaceuticals to advance the clinical development of its therapy T-Guard for treating steroid-refractory acute graft-versus-host disease.

Information on the Target

Xenikos B.V. is a clinical-stage biopharmaceutical company based in Nijmegen, the Netherlands, focused on developing innovative therapies for immune-related disorders. The company's flagship product, T-Guard®, is engineered to reset the immune system in life-threatening conditions, particularly acute graft-versus-host disease (aGVHD). Currently, Xenikos is preparing to initiate a registrational Phase 3 clinical trial in both the United States and the European Union to evaluate the safety and efficacy of T-Guard for patients suffering from steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic stem cell transplantation.

T-Guard presents a unique mechanism of action utilizing toxin-conjugated monoclonal antibodies that target CD3 and CD7 on immune cells. Preclinical and initial clinical trials have demonstrated promising results, including significantly higher complete response rates and improved overall survival rates when compared to historical controls. The treatment has been designated as an Orphan Drug in both the US and EU, highlighting its potential significance in addressing unmet medical needs in the field of transplantation.

Industry Overview in the Target’s Specific Country

The biopharmaceutical industry in the Netherlands is recognized for its innovative research and development capabilities. The country boasts a robust framework for drug development, powered by collaborations between universities, researc